AMPHAmphastar Pharmaceuticals, Inc.

1. Aug 6, 2026Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026.Earnings release · press release
2. Jul 13, 2026On July 9, 2026, the Board of Directors (the “Board”) of Amphastar Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), approved an increase to the authorized number of directors permitted to serve on the Board …Director or officer change · Form 8-K
3. Jul 8, 2026On July 2, 2026, International Medication Systems, Limited (“IMS”), a subsidiary of the Company, received a warning letter (the "Warning Letter") from the FDA relating to IMS's drug manufacturing facility located in South El Monte, California.Other event · Form 8-K
4. May 7, 2026Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026.Earnings release · press release
5. Mar 16, 2026On March 12, 2026, the Company’s Board of Directors authorized a $50 million increase to the Company’s share buyback program, which is expected to continue for an indefinite period of time.Other event · Form 8-K
6. Mar 6, 2026On March 3, 2026 (the “Effective Date”), Amphastar Pharmaceuticals, Inc. (“Amphastar” or, the “Company”), entered into executive employment agreements with each of Jacob Liawatidewi, the Company’s Executive Vice President of Corporate Administration Center, Secretary and a member of the board of directors (the …Director or officer change · Form 8-K
7. Mar 6, 2026On March 3, 2026, (the “Effective Date”), Amphastar Nanjing Pharmaceuticals, Inc. (“ANP”), the Chinese subsidiary of Amphastar Pharmaceuticals, Inc. (“Amphastar” or, the “Company”), entered into a supply agreement (the “Supply Agreement”) with Nanjing Letop Biotechnology Co., Ltd. (“Letop”)Material agreement entered · Form 8-K
8. Feb 26, 2026Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025.Earnings release · press release
9. Jan 12, 2026Material Definitive Agreement.Material agreement entered · Form 8-K
10. Nov 6, 2025Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025.Earnings release · press release
11. Oct 24, 2025On October 21, 2025 (the “Effective Date”) Amphastar Pharmaceuticals, Inc. (“Amphastar”), a wholly-owned subsidiary of Amphastar Pharmaceuticals, Inc. (the “Company”), and Nanjing Chengong Pharmaceutical Co., Limited (“Chengong”), a wholly-owned subsidiary of Nanjing Hanxin Pharmaceutical Technology Co., Ltd. …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.